IRTUM – Institutional Repository of the Technical University of Moldova

The Implementation of Personalized Medicine in the Republic of Moldova: Challenges and Opportunities in Cardiology

Show simple item record

dc.contributor.author LEVITCHI, Alexei
dc.contributor.author GALEA-ABDUSA, Daniela
dc.contributor.author SONTEA, Victor
dc.contributor.author CUROCICHIN, Ghenadie
dc.date.accessioned 2023-11-15T08:13:44Z
dc.date.available 2023-11-15T08:13:44Z
dc.date.issued 2023
dc.identifier.citation LEVITCHI, Alexei, GALEA-ABDUSA, Daniela, SONTEA, Victor et al. The Implementation of Personalized Medicine in the Republic of Moldova: Challenges and Opportunities in Cardiology. In: 6th International Conference on Nanotechnologies and Biomedical Engineering: proc. of ICNBME-2023, 20–23, 2023, Chisinau, vol. 2: Biomedical Engineering and New Technologies for Diagnosis, Treatment, and Rehabilitation, 2023, p. 288-298. ISBN 978-3-031-42781-7. e-ISBN 978-3-031-42782-4. en_US
dc.identifier.isbn 978-3-031-42781-7
dc.identifier.isbn 978-3-031-42782-4
dc.identifier.uri https://doi.org/10.1007/978-3-031-42782-4_31
dc.identifier.uri http://repository.utm.md/handle/5014/24805
dc.description Acces full text - https://doi.org/10.1007/978-3-031-42782-4_31 en_US
dc.description.abstract Implementing Personalized Medicine in the operational and functional context of a healthcare system is a complex challenge for most countries. Pharmacogenetics represents the application domain of individual genetic profile testing for drug prescription purposes. Health insurance systems are the mechanism by which drug treatment expenses can be covered. Doctors prescribe treatments based on a patient's clinical evaluation, according to the results of clinical studies that demonstrated the efficacy and low risk of adverse reactions of a particular drug tested on a clearly defined group of patients. Historically, most of these studies missed the assessment of individual capacity to metabolize drugs through xenobiotic transformation pathways. Proteins involved in transforming drug's chemical forms have yet to be well known, and studying their activity mechanisms is complex from a methodological point of view. Structural changes in the genes coding these proteins demonstrated an association with drug metabolism capacity, as revealed by GWAS studies for some populations. Inequality in sample collection and access limited the representativeness of many populations, with statistical significance levels being reached only for some of them. Validation of GWAS associations would allow their application in pharmacogenetic testing services in an evidence-based manner. This study represents a survey of the current opportunities to implement recommended genetic testing for the drugs used in CVD treatment compensated for the population by the National Health Insurance Company in the Republic of Moldova. en_US
dc.language.iso en en_US
dc.publisher Springer Nature Switzerland en_US
dc.rights Attribution-NonCommercial-NoDerivs 3.0 United States *
dc.rights.uri http://creativecommons.org/licenses/by-nc-nd/3.0/us/ *
dc.subject personalized medicine en_US
dc.subject pharmacogenetics en_US
dc.subject cardiology en_US
dc.subject healthcare system en_US
dc.title The Implementation of Personalized Medicine in the Republic of Moldova: Challenges and Opportunities in Cardiology en_US
dc.type Article en_US


Files in this item

The following license files are associated with this item:

This item appears in the following Collection(s)

  • 2023
    6th International Conference on Nanotechnologies and Biomedical Engineering, September 20–23, 2023, Chisinau, Moldova

Show simple item record

Attribution-NonCommercial-NoDerivs 3.0 United States Except where otherwise noted, this item's license is described as Attribution-NonCommercial-NoDerivs 3.0 United States

Search DSpace


Browse

My Account